Peptide • Metabolism, weight & diabetes
Retatrutide
What it is, the potential benefits being studied, and what the evidence supports right now.
Promising human research•Research-stage compound•Checked 2026-08-21
01 • Start here
Potential benefits being studied.
Obesity and related metabolic outcomes.
- Weight & body composition
- Metabolic health
02 • Why it stands out
The simple explanation.
Retatrutide combines three metabolic hormone signals in one molecule, making it one of the most closely watched weight-management compounds in development.
03 • Research highlight
Why researchers are interested.
Its standout feature is the scale of weight loss reported so far, which makes it one of the most exciting metabolic compounds to watch.
Evidence detailsStudy limits, status, and safety context
Study summary: Phase 2 randomized evidence and Lilly-reported 2026 Phase 3 topline results show substantial average weight reduction in studied obesity populations.
What to keep in mind: The Phase 3 figures are manufacturer-reported topline results pending complete peer-reviewed reporting. Retatrutide remains investigational, and no online research product inherits the trial program's identity or controls.
Potential benefits describe research questions, not a promise that a product will produce the same result in a person.